Nuvation Bio Files 8-K on Operations and Financials
Ticker: NUVB · Form: 8-K · Filed: Aug 7, 2025 · CIK: 1811063
Sentiment: neutral
Topics: operations, financials, reporting
Related Tickers: NUVB
TL;DR
Nuvation Bio dropped an 8-K on Aug 7th covering financials and operations.
AI Summary
Nuvation Bio Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company, formerly known as Panacea Acquisition Corp. until April 30, 2020, is incorporated in Delaware and headquartered in New York, NY.
Why It Matters
This 8-K filing provides an update on Nuvation Bio's operational and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting operational and financial information, not indicating any immediate material adverse events.
Key Players & Entities
- Nuvation Bio Inc. (company) — Registrant
- Panacea Acquisition Corp. (company) — Former company name
- August 7, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- New York, NY (location) — Principal executive offices address
FAQ
What is the primary purpose of this 8-K filing for Nuvation Bio Inc.?
The primary purpose is to report on the company's Results of Operations and Financial Condition, along with providing Financial Statements and Exhibits.
When was Nuvation Bio Inc. formerly known as Panacea Acquisition Corp.?
Nuvation Bio Inc. was formerly known as Panacea Acquisition Corp. until April 30, 2020.
In which state is Nuvation Bio Inc. incorporated?
Nuvation Bio Inc. is incorporated in Delaware.
What is the address of Nuvation Bio Inc.'s principal executive offices?
The principal executive offices are located at 1500 Broadway, Suite 1401, New York, NY 10036.
What is the SIC code for Nuvation Bio Inc.?
The Standard Industrial Classification (SIC) code for Nuvation Bio Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-08-07 07:30:18
Key Financial Figures
- $0.0001 — xchange on which Class A Common Stock, $0.0001 par value per share NUVB The New Yo
- $11.50 — of Common Stock at an exercise price of $11.50 per share NUVB.WS The New York Stoc
Filing Documents
- d909051d8k.htm (8-K) — 27KB
- d909051dex991.htm (EX-99.1) — 114KB
- g909051g0806225058834.jpg (GRAPHIC) — 4KB
- 0001193125-25-174954.txt ( ) — 312KB
- nuvb-20250807.xsd (EX-101.SCH) — 4KB
- nuvb-20250807_def.xml (EX-101.DEF) — 14KB
- nuvb-20250807_lab.xml (EX-101.LAB) — 23KB
- nuvb-20250807_pre.xml (EX-101.PRE) — 15KB
- d909051d8k_htm.xml (XML) — 6KB
FINANCIAL STATEMENTS AND EXHIBITS
FINANCIAL STATEMENTS AND EXHIBITS (d) Exhibits. Exhibit Number Description 99.1 Press Release of Nuvation Bio Inc. dated August 7, 2025. 104 Cover Page Interactive Data File (embedded within XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 7, 2025 NUVATION BIO INC. By: /s/ Philippe Sauvage Name: Philippe Sauvage Title: Chief Financial Officer 3